Beta-blocker (BB) therapy is a main pillar in treating patients with heart failure and reduced
ejection fraction and has shown a prognostic benefit. However, evidence for application of …

Objective: To review the pharmacology, pharmacokinetics, and pharmacodynamic
properties of commonly used β-blockers (atenolol, carvedilol, metoprolol succinate …

Objectives To determine the effects of nebivolol on oxidative stress, insulin resistance,
adiponectin and plasma soluble P-selectin levels in hypertensive patients in comparison …

Bisoprolol and nebivolol are highly selective β1-adrenoceptor antagonists, with clinical
indications in many countries within the management of heart failure with reduced left …

Although well established in treating hypertension and cardiovascular (CV) disease, clinical
trial data suggest that β-blockers (eg, atenolol) may be less effective than other …

Cardioselective β-blockade is generally well tolerated in practice and contraindications to
this therapy are uncommon. β-blockers are a diverse therapeutic class, and their individual …

Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …

Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …

Objectives To compare the effects of nebivolol and atenolol in 25 ambulatory hypertensive
patients with impaired glucose tolerance. Design Clinic and ambulatory blood pressure …

Nebivolol is a new selective β1-adrenergic blocking agent, that possesses a peculiar
pharmacodynamic profile and an original chemical structure, by which it differs from …